Yaozhen Pan

机构：Guiyang Medical University, Guizhou Cancer Hospital, Affiliated Hospital of Guizhou Medical University · ORCID：0000-0002-9300-382X

发表论文 38 篇 · 总被引 491 次 · h-index 11

代表论文

• Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 49)
• FAM126A interacted with ENO1 mediates proliferation and metastasis in pancreatic cancer via PI3K/AKT signaling pathway (2022 · Cell Death Discovery · 被引 28)
• Endoscopic management of biliary ascariasis: A case report (2021 · World Journal of Clinical Cases · 被引 12)
• PELI1: key players in the oncogenic characteristics of pancreatic Cancer (2024 · Journal of Experimental & Clinical Cancer Research · 被引 11)
• The deubiquitinating enzyme MINDY2 promotes pancreatic cancer proliferation and metastasis by stabilizing ACTN4 expression and activating the PI3K/AKT/mTOR signaling pathway (2023 · Frontiers in Oncology · 被引 11)
• FBXW7 Reduces the Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma by Regulating the Ubiquitination and Degradation of ACTL6A (2022 · Stem Cells International · 被引 11)